Perifosine May Offer New Mesothelioma Treatment
The makers of the anti-cancer drug perifosine say new research suggests the drug may offer a new way to fight malignant mesothelioma. The research article entitled “Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma” was recently published in the peer-reviewed online medical journal Plos One. The announcement has been picked up by other news outlets because of the rarity of new treatments for mesothelioma, the asbestos-linked cancer that is diagnosed in about 2,500 Americans every year. In the new study, perifosine was tested on human mesothelial cells and a variety of mesothelioma cell lines to demonstrate its effectiveness alone or in combination with other mesothelioma treatments. When given at a high enough dose, perifosine interfered…